Company

• A global biopharma focused on severe diseases in three therapeutic areas:

• Central nervous system
• Inflammation
• Oncology

UCB also has a selective presence in primary care

• Global revenue of €3.6 billion in 2007
• Operations in over 40 countries, supported by more than 10,000 staff
• Established in 1928, successful transformation from a hybrid specialty chemical company into a next generation biopharma leader
• Listed on the Euronext Brussels Stock Exchange
• Headquartered in Brussels, Belgium.